AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019

Mar 19, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-03-15

Reporting Person: Bowden Christopher (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-15	Common stock	M	10000	$35.16	Acquired	17238	Direct
2019-03-15	Common stock	S	8700	$64.09	Disposed	8538	Direct
2019-03-15	Common stock	S	1300	$64.64	Disposed	7238	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-15	Stock option (right to buy)	$35.16	M	10000	Disposed	2024-05-30	Common stock (10000)	Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Includes 43 shares purchased through the Company's employee stock purchase plan.

F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $63.54 to $64.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $64.59 to $64.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.